| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,111,521 | 33 | 100 |
| Bowen Matthew | Principal Accounting Officer | 0 | $0 | 1 | $137 | $-137 |
| Nickson Philip | Chief Business & Legal Officer | 0 | $0 | 2 | $151,274 | $-151,274 |
| Champoux Jennifer | Chief Operating Officer | 0 | $0 | 6 | $311,300 | $-311,300 |
| Manning Anthony M. | director | 0 | $0 | 2 | $411,200 | $-411,200 |
| Townson Sharon | Chief Scientific Officer | 0 | $0 | 5 | $423,931 | $-423,931 |
| Dunn Edmund | Principal Accounting Officer | 0 | $0 | 4 | $483,144 | $-483,144 |
| Warmuth Markus | President & CEO | 0 | $0 | 7 | $951,138 | $-951,138 |
| Janku Filip | Chief Medical Officer | 0 | $0 | 6 | $1.38M | $-1.38M |
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and …
Over the last 12 months, insiders at Monte Rosa Therapeutics, Inc. have bought $0 and sold $4.11M worth of Monte Rosa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Monte Rosa Therapeutics, Inc. have bought $58,383 and sold $5.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $58,383 was made by Leo Chandra P. (director) on 2025‑03‑24.
| 2026-10-05 | Sale | Bowen Matthew | Principal Accounting Officer | 13 <0.0001% | $10.56 | $137 | +2.43% | |
| 2026-07-16 | Sale | Warmuth Markus | President & CEO | 9,500 0.0146% | $23.18 | $220,219 | -40.24% | |
| 2026-07-15 | Sale | Champoux Jennifer | Chief Operating Officer | 4,351 0.0067% | $23.38 | $101,730 | -40.75% | |
| 2026-07-06 | Sale | Townson Sharon | Chief Scientific Officer | 6,000 0.0092% | $23.31 | $139,849 | -38.84% | |
| 2026-06-30 | Sale | Janku Filip | Chief Medical Officer | 5,407 0.0084% | $24.50 | $132,472 | -41.05% | |
| 2026-06-29 | Sale | Janku Filip | Chief Medical Officer | 6,000 0.0088% | $22.95 | $137,700 | -40.29% | |
| 2026-06-29 | Sale | Manning Anthony M. | director | 10,000 0.0148% | $23.11 | $231,100 | -40.29% | |
| 2026-06-24 | Sale | Janku Filip | Chief Medical Officer | 30,000 0.0477% | $21.42 | $642,681 | -31.39% | |
| 2026-06-23 | Sale | Townson Sharon | Chief Scientific Officer | 3,000 0.0044% | $20.00 | $60,000 | -30.90% | |
| 2026-06-23 | Sale | Champoux Jennifer | Chief Operating Officer | 2,175 0.0032% | $20.00 | $43,500 | -30.90% | |
| 2026-06-23 | Sale | Janku Filip | Chief Medical Officer | 11,845 0.0178% | $20.22 | $239,522 | -30.90% | |
| 2026-06-17 | Sale | Townson Sharon | Chief Scientific Officer | 3,000 0.0048% | $19.00 | $57,000 | -22.22% | |
| 2026-06-17 | Sale | Champoux Jennifer | Chief Operating Officer | 2,176 0.0034% | $19.00 | $41,344 | -22.22% | |
| 2026-06-01 | Sale | Warmuth Markus | President & CEO | 5,466 0.0083% | $19.44 | $106,253 | -22.70% | |
| 2026-05-29 | Sale | Townson Sharon | Chief Scientific Officer | 6,000 0.0093% | $19.87 | $119,220 | -21.97% | |
| 2026-05-27 | Sale | Champoux Jennifer | Chief Operating Officer | 2,175 0.0035% | $20.00 | $43,500 | -19.77% | |
| 2026-05-22 | Sale | Champoux Jennifer | Chief Operating Officer | 2,176 0.0034% | $19.00 | $41,344 | -17.60% | |
| 2026-05-21 | Sale | Manning Anthony M. | director | 10,000 0.0146% | $18.01 | $180,100 | -17.61% | |
| 2026-05-01 | Sale | Warmuth Markus | President & CEO | 5,467 0.0084% | $18.92 | $103,447 | -15.35% | |
| 2026-04-14 | Sale | Warmuth Markus | President & CEO | 8,000 0.012% | $17.64 | $141,125 | -2.86% |
| MAKOWER JOSHUA | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Mathers Edward T | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Walker Paul Edward | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Behbahani Ali | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% | |
| Landsman Liza | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Makhzoumi Mohamad | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Chang Carmen | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| New Enterprise Associates 17, L.P. | director | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Yang Rick | 10 percent owner | 7692298 9.0165% | $80.08M | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 3202200 3.7535% | $33.33M | 1 | 0 | <0.0001% | |
| Bolzon Bradley J PhD | 2097938 2.4591% | $21.84M | 1 | 0 | <0.0001% | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 1573453 1.8443% | $16.38M | 1 | 6 | <0.0001% |
| Leo Chandra P. | director | 10000 0.0117% | $104,100.00 | 1 | 0 | +13.55% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$11,663,618 | 57 | 32.20% | $934.29M |
| Increased Positions | 101 | +79.53% | 14M | +24.13% |
| Decreased Positions | 54 | -42.52% | 9M | -15.32% |
| New Positions | 49 | New | 9M | New |
| Sold Out Positions | 16 | Sold Out | 2M | Sold Out |
| Total Postitions | 174 | +37.01% | 64M | +8.81% |
| Nea Management Company, Llc | $117,769.00 | 11.83% | 7.69M | 0 | 0% | 2025-09-30 |
| Bvf Inc/Il | $86,657.00 | 8.71% | 5.66M | 0 | 0% | 2025-09-30 |
| Versant Venture Management, Llc | $86,546.00 | 8.7% | 5.65M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $75,265.00 | 7.56% | 4.92M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $70,993.00 | 7.13% | 4.64M | -2M | -26.69% | 2025-09-30 |
| Blackrock, Inc. | $58,410.00 | 5.87% | 3.82M | -31,321 | -0.81% | 2025-09-30 |
| Suvretta Capital Management, Llc | $51,442.00 | 5.17% | 3.36M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $45,761.00 | 4.6% | 2.99M | -151,557 | -4.83% | 2025-09-30 |
| Fmr Llc | $43,056.00 | 4.33% | 2.81M | +524,217 | +22.91% | 2025-09-30 |
| Aisling Capital Management Lp | $22,541.00 | 2.27% | 1.47M | 0 | 0% | 2025-09-30 |